Antiviral⁢ Treatment Fails to Slow Early-Stage Alzheimer’s, study Finds

Herpes Simplex Virus and Alzheimer’s Link Explored in Clinical ⁤Trial

Approximately 60% to 70% of Americans are infected with herpes simplex viruses (HSV), commonly causing cold sores (HSV1) and‍ genital​ herpes‌ (HSV2). After initial symptoms‌ subside, these‌ viruses can lie dormant within the‍ nervous ⁢system, periodically ‌reactivating and causing‍ flare-ups. Recent research⁢ has ⁢explored ‌a potential link‍ between ⁤herpes infections‍ and‌ Alzheimer’s disease.Autopsy studies have⁢ revealed HSV1 DNA frequently enough associated with amyloid plaques in ​the brains of individuals diagnosed with Alzheimer’s.Furthermore, some studies suggest that people treated for ⁤herpes infections may be less likely to develop Alzheimer’s later ‌compared ⁢to untreated‍ HSV-positive individuals.

“Based on those previous studies, ⁢there​ was hope that valacyclovir could have an ⁣effect,” stated D.P. Devanand, MD, lead​ investigator of the trial, professor of psychiatry ‍and neurology, and director of geriatric‌ psychiatry. “But no​ one ⁣had⁢ conducted a clinical ⁣trial to test the idea.”

Trial⁢ Details⁣ and⁢ Findings

To ​investigate this‌ potential connection, a clinical trial was conducted involving 120 adults, ‍with an average age ⁣of⁤ 71. All participants had⁤ been diagnosed with early Alzheimer’s ​disease ⁤or mild cognitive impairment, with‍ imaging or blood tests confirming Alzheimer’s pathology. Crucially, all participants exhibited antibodies indicating past herpes infections, predominantly HSV1, with some also having​ HSV2.

Participants were randomly assigned to ⁣receive either daily pills containing​ valacyclovir, an⁢ antiviral medication, or a placebo. The researchers monitored participants’ memory⁢ functions and⁢ used⁢ brain⁢ imaging to detect‌ amyloid and tau‍ deposits,‌ hallmarks of Alzheimer’s, as well as other structural ⁣brain changes.

After 18 months,the study revealed no ‌important benefits from valacyclovir treatment. In fact, participants taking ‍the placebo ‍performed‍ slightly better on cognitive tests than those receiving valacyclovir. Other⁤ measured outcomes showed​ no significant ⁣differences between the two groups.

“We were looking ⁢for ⁤a signal that the drug did better than the placebo, but there wasn’t any in this study,” Dr. Devanand ‍commented. “On ​the other measures, sometimes⁤ the⁤ placebo group did slightly‌ better,⁢ sometimes the treatment group ⁤did slightly better.”

The trial’s results ‌remained consistent across different ⁤age groups, sexes, and apolipoprotein E e4 (APOE e4) genetic ‍status,⁣ a known risk‌ factor for Alzheimer’s.”Our trial ⁢suggests antivirals that target herpes are not effective in ⁣treating early Alzheimer’s and cannot be recommended to⁤ treat such patients with ⁢evidence of‍ prior HSV ​infection,” concluded ‌Dr. ‍Devanand. “We do not know if long-term‍ antiviral medication treatment following herpes infection can prevent‌ Alzheimer’s because prospective controlled trials have⁤ not been conducted.”

Source: Columbia University Irving Medical Center